Overview

Avatrombopag for the Treatment of Chemotherapy-Induced Thrombocytopenia in Adults With Active Non-Hematological Cancers

Status:
Active, not recruiting
Trial end date:
2025-08-01
Target enrollment:
Participant gender:
Summary
Phase 3 randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of avatrombopag in subjects with chemotherapy-induced thrombocytopenia receiving chemotherapy for the treatment of ovarian, lung (small cell and non-small cell) and bladder cancer.
Phase:
Phase 3
Details
Lead Sponsor:
Dova Pharmaceuticals